AstraZeneca advances on omicron vaccine 0:39
(CNN) -
Three doses of AstraZeneca's covid-19 vaccine offer "significantly increased antibody levels" against the omicron variant of the coronavirus, the drug company said Thursday, citing a new Oxford University study.
The laboratory study found that three doses of the AstraZeneca vaccine offered levels of antibodies against omicron comparable to those generated against the delta variant after the primary immunization regimen of two injections.
Minute by minute: the progress of the omicron variant and the situation of covid-19 in the world
The findings, which have yet to be published in a peer-reviewed medical journal, also showed that antibody levels generated in patients who received an AstraZeneca booster vaccine were higher than those seen in people who had been infected and recovered. naturally from covid-19.
The study analyzed blood samples taken from 41 people who had received three doses of the AstraZeneca vaccine, along with blood samples from people who had received only two doses and who had recovered naturally from a previous Covid-19 infection. .
Researchers involved in the new Oxford University study were not involved in the development of AstraZeneca's covid-19 vaccine, the drug company said in its press release Thursday.
Bill Gates' warning about omicron in the US: We could be entering the worst part of the pandemic
AstraZeneca and the University of Oxford work on a vaccine against the omicron variant
The pharmaceutical company AstraZeneca together with the University of Oxford are taking preliminary steps to produce a vaccine against the omicron variant, the company reported to CNN.
So far, omicron is the dominant variant in the US, Denmark, Portugal and the UK.
advertising
AstraZeneca advances on omicron vaccine 0:39
AstraZenecaomicron
